Cemiplimab plus chemotherapy improves outcomes in metastatic NSCLC
Click Here to Manage Email Alerts
Key takeaways:
- Cemiplimab plus chemotherapy improved outcomes in patients with metastatic NSCLC compared with chemotherapy alone.
- The safety profile was consistent with other study populations.
MADRID — A treatment regimen of cemiplimab plus chemotherapy showed improvement over chemotherapy alone, according to research presented at ESMO Congress.
“In these patients, we got very amazing results,” Ana Baramidze, MD, of the Todua Clinic, in Tbilisi, Georgia, told Healio.
Baramidze and colleagues used data from the randomized, double-blind, placebo-controlled phase 3 EMPOWER-Lung 3 trial assessing the use of cemiplimab (Libtayo, Regeneron Pharmaceuticals) plus chemotherapy vs. chemotherapy alone.
Patients were randomly assigned 2:1 to receive four cycles of platinum-doublet chemotherapy combined with 350 mg cemiplimab or placebo every 3 weeks for up to 108 weeks.
They found that among 327 patients with a PD-L1 of at least 1%, the median OSwas longer among patients who received cemiplimab plus chemotherapy vs. chemotherapy alone (23.5 vs 12.1 months; HR = 0.52, P < 0.0001).
Baramidze told Healio that these were “very good results.”
They also found that, among patients who received cemiplimab plus chemotherapy, median PFS was 8.3 months, compared with 5.5 months in patients who received chemotherapy alone (HR = 0.47; P < 0.0001), and the objective response rate was 47.9% vs. 22.7%. The response duration was 17.5 months in those who received the study treatment and 6.5 months in those who received placebo.
The researchers noted grade 3 or greater treatment-emergent adverse events in 48.4% of patients who received cemiplimab and in 27.5% of those who received placebo.
They also found that cemiplimab plus chemotherapy in patients with PD-L1 of 1% or greater had a safety profile consistent with the overall patient population.
Collapse
Baramidze A, et al. Abstract 1495P. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Read more about
Click Here to Manage Email Alerts